Explore the efficacy and safety of targeted small molecule drug TYK2 inhibitors in combination with and without calcipotriol betamethasone for the treatment of adult moderate to severe plaque psoriasis.

开始日期2024-11-01

申办/合作机构-

NCT05919082

/ Completed临床3期

A Phase 3, Randomised, Investigator-blind, Active-controlled, Parallel Group, Multicentre Trial Comparing the Efficacy and Safety of 4-weeks Treatment With LEO 90100 and Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis

This study is conducted to assess the efficacy and safety of LEO 90100 when used on the body for the treatment of stable plaque psoriasis in native adult Chinese subjects, compared to Daivobet® ointment.

开始日期2023-06-21

申办/合作机构

Leo Pharma, Inc.

CTR20223222

/ Completed临床3期

一项在中国稳定性斑块状银屑病成人受试者中比较LEO 90100和得肤宝 ®软膏治疗4周的有效性和安全性的III期、随机、研究者设盲、活性药物对照、平行分组、多中心试验

主要目的：评价LEO 90100与得肤宝®软膏相比对稳定性斑块状银屑病严重程度和范围的有效性。次要目的：评价LEO 90100与得肤宝®软膏相比治疗稳定性斑块状银屑病的安全性。

开始日期2023-06-21

申办/合作机构

LEO Laboratories Ltd.

[+2]

100 项与倍他米松二丙酸酯/卡泊三醇相关的临床结果

登录后查看更多信息

100 项与倍他米松二丙酸酯/卡泊三醇相关的转化医学

登录后查看更多信息

100 项与倍他米松二丙酸酯/卡泊三醇相关的专利（医药）

登录后查看更多信息

项与倍他米松二丙酸酯/卡泊三醇相关的文献（医药）

2024-03-01·Dermatology and therapy

Improvements in Plaque Psoriasis Associated with Calcipotriol/Betamethasone Aerosol Foam Treatment: A Post Hoc Analysis of Non-interventional Studies and Clinical Experience

Article

作者: Jablonski Bernasconi, Marie Y ; Halioua, Bruno ; Lazaridou, Elizabeth ; Pesiridis, Georgios ; Krogager Eeg, Martin ; Campanati, Anna ; Ratzinger, Gudrun ; Gerdes, Sascha

INTRODUCTION:

Plaque psoriasis is a chronic relapsing inflammatory skin disease that is associated with extensive disease burden that often requires long-term therapy. Treatment of psoriasis with 4 weeks of the aerosol foam formulation of calcipotriol/betamethasone dipropionate (Cal/BD; Enstilar®, LEO Pharma) has been demonstrated to be effective, well tolerated, and associated with high patient satisfaction. Cal/BD foam is approved as a first-line treatment in multiple countries, where several non-interventional studies (NIS) have corroborated the beneficial efficacy and safety profiles determined in the randomized clinical trials. Heterogenicity in these NIS, however, prevents the use of a data pooling strategy for comparisons of effectiveness outcomes across different patient populations.

METHODS:

Therefore, here, we report on a post hoc analysis of effectiveness data consolidated from six prospective NIS to discern any differences in improvement in signs and symptoms of psoriasis attributable to Cal/BD foam treatment across the countries. In addition, we provide real-world experience of clinicians with Cal/BD foam treatment, factoring in changes in usage since these NIS were performed in their local markets.

RESULTS:

This post hoc analysis of Cal/BD foam NIS brings together data outside of randomized clinical trials from six countries to provide real-world evidence in 1388 patients showing that 4 weeks of Cal/BD foam is an effective and safe treatment option with quick onset of action for patients with psoriasis.

CONCLUSION:

These results show that regardless of NIS location, Cal/BD foam remains a well-tolerated, efficacious option for patient care that could be used as a first-line topical therapy for mild-to-severe psoriasis.

2023-12-31·The Journal of dermatological treatment

Potential biomarkers for psoriasis topical treatment by in-depth serum proteomics

Article

作者: Yu, Xiaobo ; Deng, Hao ; Zhang, Xiaomei ; Lu, Chuanjian ; Yu, Jingjie ; Yao, Danni ; Cui, Jingwen ; Deng, Jingwen ; Ye, Shuyan ; Han, Ling ; Yan, Yuhong

BACKGROUND:

Psoriasis is a chronic skin disease, and topical sequential therapy with a combination of calcipotriol and calcipotriol betamethasone is currently approved topical treatment. However, the exact mechanism by which this treatment regimen relieves psoriasis is unknown.

METHOD:

We assembled a cohort of 65 psoriasis patients and divided post-treatment cohort into responder group and non-responder group according to the Psoriasis Area Severity Index (PASI) score after 12-week treatment. We measured the expression levels of proteins in collected 130 serum samples using our in-depth proteomics platform with a data-independent acquisition mass spectrometer and antibody microarray. We performed bioinformatics analyses of the biologic processes and signaling pathways that were changed in the responder group and constructed a proteomics landscape of psoriasis pathogenesis response to treatment. We then validated the biomarkers of disease severity in an independent cohort of 88 samples using an enzyme-linked immunosorbent assay.

RESULTS:

We first identified 174 differentially expressed proteins (DEPs) for comparative analysis of proteins between responders and non-responders at baseline (p < 0.05). Then pathway analysis showed that the responders focused more on signaling molecules and interaction, complement and coagulation cascades, whereas the non-responders more on signal transduction and IL-17 signaling pathways. We further identified four candidate biomarkers (COLEC11, C1QA, BNC2, ITIH4) response to treatment. We also found 125 DEPs (p < 0.05) after treatment compared with before treatment in responder group. Pathway analysis showed an enrichment in pathways related to complement and coagulation cascades, phagosome, ECM-receptor interaction, cholesterol metabolism, vitamin digestion and absorption. CD14 was validated as potential biomarkers for the disease severity of psoriasis and treatment targets.

CONCLUSION:

In this work, we analyzed the response to topical sequential therapy and finally identified four biomarkers. Additionally, we found that topical sequential therapy may alleviate psoriasis by regulating lipid metabolism and modulating the immune response by affecting the complement activation process.

2023-11-01·European review for medical and pharmacological sciences

The role of the foam formulation in improving psoriasis treatment acceptability: a real-life experience and a literature review.

Review

作者: Papa, S ; Gasparini, S ; Martella, A ; Giovene, G L

BACKGROUND:

Topical therapies represent the first-line treatment for mild-to-moderate psoriasis. Among various topical options, the fixed-dose combination of calcipotriene (Cal) and betamethasone dipropionate (BD) foam (Enstilar®, LEO Pharma, Ballerup, Denmark) showed superior efficacy to Cal and BD monotherapy and ointment and gel formulations. In addition, the Cal/BD foam is the only topical treatment allowed for either reactive treatment of relapse or twice-weekly maintenance use. Since treatment acceptability is crucial to optimize adherence, this paper presents a case series from a multicenter experience using the Cal/BD foam, to further characterize the use of this therapeutic approach. In addition, a narrative review of studies evaluating the acceptability of the Cal/BD foam, even compared with other formulations, is provided.

CASE SERIES:

The case series involved adult patients with mild-to-moderate psoriasis treated with the Cal/BD foam from October 2021 to June 2022. A clinical and dermoscopic evaluation of plaques was provided for all patients. Data from the clinical practice report complete clinical resolution of plaques in most patients after 4 weeks of active treatment with the Cal/BD foam, and the dermoscopic clearance after a maximum of 8 weeks. Full adherence to treatment was also reported. Literature evidence suggests that the Cal/BD foam is easy to apply and presents high cosmetic acceptance, rapid onset of action, high efficacy, optimal safety, and a high patient preference. The high satisfaction obtained with Cal/BD foam suggests that this formulation is better accepted than others.

CONCLUSIONS:

The Cal/BD foam represents a valuable approach for managing mild-to-moderate psoriasis, both in short and long-term treatment.

项与倍他米松二丙酸酯/卡泊三醇相关的新闻（医药）

2024-12-18

·华东医药股份有限公司

华东医药创新皮肤外用制剂罗氟司特乳膏两项Ⅲ期临床试验完成首例受试者入组

近日，华东医药股份有限公司（以下简称“公司”）全资子公司杭州中美华东制药有限公司（以下简称“中美华东”）开展的评价0.15%罗氟司特乳膏（ZORYVE®）在轻中度特应性皮炎患者中有效性和安全性的多中心、随机、双盲、赋形剂对照的Ⅲ期桥接研究在上海复旦大学附属华山医院完成首例受试者入组及给药；一项多中心、随机、双盲、赋形剂对照的评价0.3%罗氟司特乳膏（ZORYVE®）治疗中国斑块状银屑病的有效性和安全性的Ⅲ期临床研究在北京大学人民医院完成首例受试者入组及给药。罗氟司特是一种磷酸二酯酶-4（PDE4）抑制剂，可增加促炎介质的生成并减少抗炎介质的生成，抑制PDE4可减轻炎症反应。罗氟司特乳膏是中美华东与美国纳斯达克上市公司Arcutis Biotherapeutics, Inc.（NASDAQ: ARQT）（以下简称“Arcutis”）于2023年8月签署合作协议引进的创新皮肤外用制剂产品，中美华东拥有该产品在大中华区及东南亚的独家许可。0.3%罗氟司特乳膏（ZORYVE®）于2022年7月获得美国FDA批准，用于治疗12岁及以上患者的斑块状银屑病，2023年4月在加拿大获批相同适应症，2023年10月在美国获批斑块状银屑病适应症扩展人群至6-11岁儿科人群；0.15%罗氟司特乳膏（ZORYVE®）于2024年7月获得美国FDA批准，用于治疗6岁及以上患者的轻度至中度特应性皮炎。在银屑病治疗领域，公司目前已布局生物制剂乌司奴单抗注射液、口服小分子药物环孢素软胶囊、单方外用制剂ZORYVE®乳膏剂和泡沫剂以及复方外用制剂Wynzora®乳膏，形成了多靶点、多作用机制的银屑病产品组合，可实现全周期全人群覆盖。其中，公司乌司奴单抗注射液（赛乐信®）（研发代码：HDM3001/QX001S）的上市许可申请在2024年10月获得批准，用于治疗成年中重度斑块状银屑病，为国产首家，儿童斑块状银屑病的补充申请于2024年12月获得受理。本次0.15%罗氟司特乳膏和0.3%罗氟司特乳膏两项Ⅲ期临床试验均完成了首例受试者入组，是产品研发进程中的重要里程碑，将进一步提高公司在自身免疫性及炎症性皮肤病领域的核心竞争力。公司后续将继续全力推进该款产品的临床开发及注册工作，争取为中国银屑病和特应性皮炎临床患者提供更多的治疗选择。声明 1、本新闻旨在分享公司（或合作伙伴）研发工作的前沿进展资讯，非广告用途，相关信息并非针对患者，仅供医疗卫生专业人士参考使用； 2、本新闻稿中内容不涉及对任何药品和/或适应症作推荐； 3、本新闻稿中涉及的信息仅供参考，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。 4、截止本文发布，0.15%罗氟司特乳膏（ZORYVE®）与0.3%罗氟司特乳膏（ZORYVE®）尚未被国家药品监督管理局批准上市； 5、本新闻稿中可能会包含某些前瞻性表述。这些表述本质上具有相当风险和不确定性。在使用“预期”、“相信”、“预测”、“期望”、“打算”及其他类似词语进行表述时，凡与本公司有关的，均属于前瞻性表述。本公司并无义务不断地更新这些预测性陈述。这些前瞻性表述是基于本公司管理层在做出表述时对未来事务的现有看法、假设、期望、估计、预测和理解。这些表述并非对未来发展的保证，会受到风险、不确性及其他因素的影响，有些是超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司、本公司董事及雇员代理概不承担 (a) 更正或更新本网站所载前瞻性表述的任何义务;及 (b) 若因任何前瞻性表述不能实现或变成不正确而引致的任何责任。

临床3期上市批准

2024-11-20

·药事纵横

盐酸米诺环素泡沫剂获批上市，国内泡沫剂研发竞赛拉开序幕

一、背景 2024年11月05日，科笛生物医药（上海）有限公司「盐酸米诺环素泡沫剂」(规格：4%)获得中国国家药品监督管理局（NMPA）批准在中国上市，用于治疗九岁或以上患者的非结节性中度至重度寻常痤疮炎症性病变的局部治疗。据笔者了解，该药获得了国家药监局药品审评中心优先审评审批资格。这是目前国内批准的首款盐酸米诺环素外用制剂，也是首款在国内上市销售的原研进口泡沫剂产品。 4%盐酸米诺环素泡沫剂（商品名：Amzeeq®）最早是由位于以色列的一家专门从事泡沫剂产品开发的制药公司Foamix Pharmaceuticals（2020年与Menlo Therapeutics合并成为其全资子公司）研发，于2019年10月18日被美国食品药品监督管理局（FDA）批准上市。2020年4月，Foamix与科笛生物（Cutia Therapeutics）达成协议，将包括Amzeeq®盐酸米诺环素泡沫剂在内的多个盐酸米诺环素外用制剂产品在大中华区的独家许可权授予科笛生物，向科笛供应用于临床和商业用途的许可产品。根据公开的信息，Foamix通过该授权可获得1000万美元的预先现金付款，产品一旦在中国获批上市销售，还将获得额外的100万美元付款。此外，根据协议Foamix还会根据科笛在大中华区销售这些被许可产品的净销售额，获得一定比例的版税收入。科笛生物于2021年在中国境内开展了一项评价盐酸米诺环素泡沫剂（4%）局部给药治疗中度至重度寻常痤疮的多中心、随机、双盲、安慰剂对照的有效性和安全性的III期注册性临床试验。研究结果显示，经过12周后治疗后，治疗炎性皮损的改善相较于安慰剂组展现出了显著的改善，达到主要终点指标。在安全性方面，治疗组受试者对给药部位局部表现出了良好的耐受性。治疗组与安慰剂组在不良事件的总发生率上相当，且均未报告有药物相关的严重不良事件。口服盐酸米诺环素治疗痤疮疗效较差且容易引起全身的毒副作用，而4%盐酸米诺环素泡沫剂作为的首款盐酸米诺环素的外用制剂成功实现了盐酸米诺环素的局部外用给药，不仅疗效显著且大大降低了口服给药带来的不良反应，具有里程碑意义。笔者曾于2023年9月在本公众号（“药事纵横”）上发表了《浅析盐酸米诺环素油泡沫剂处方设计及泡沫形成原理》一文，简要介绍了盐酸米诺环素外用制剂开发面临的挑战以及其泡沫剂处方及发泡原理。具体来说，Foamix利用了其独特的分子稳定技术（Molecular Stabilizing Technology, MST）技术，有效解决了盐酸米诺环素药物的稳定性（如对光、氧、水、某些质子性溶剂和表面活性剂等不稳定）问题，成功开发出了无水、无表面活性剂的盐酸米诺环素泡沫剂。该技术将微粉化的盐酸米诺环素分散在大量的油性基质中，利用抛射剂汽化后处方中高级脂肪醇和高级脂肪酸吸附空气-油界面，形成稳定的油泡沫，方便患者涂抹于患处。二、关于泡沫剂泡沫剂（foam）是指将原料药和辅料灌装到加压容器或者非加压容器后将内容物呈泡沫状喷出一类药物制剂。前者需要填充抛射剂才能形成在喷出后形成泡沫，因此又称“泡沫气雾剂”（foam aerosol）。在国内，一般提到泡沫剂都默认指的是泡沫气雾剂。泡沫剂具有吸附性强、易于涂布、美观、经皮渗透能力强等优点。此外，对于腔道给药，泡沫剂给药后泡沫能够迅速在腔道内（如阴道、直肠等）充盈，覆盖给药部位，给药便捷，这是很多传统剂型所不具备的优势。美国FDA迄今已批准了18种泡沫剂NDA上市申请，其最早批准的一款泡沫剂产品可以追溯到1999年上市的戊酸倍他米松泡沫剂（见本公众号文章《盘点泡沫气雾剂给药系统中应用的平台技术》）。目前除了盐酸米诺环素泡沫剂的进口上市申请已经获批，笔者注意到利奥制药（LEO Pharma）也于近期正式向国家药品管理局提交了Enstilar®泡沫剂（卡泊三醇/丙酸倍他米松泡沫剂）进口上市许可申请。在国内，2023年12月中国药品监督管理局才批准第一款化药泡沫剂产品——米诺地尔泡沫剂仿制药上市。截至目前，尚没有一款国内企业自主研发的泡沫剂NDA上市申请获批。但是，从国家药品监督管理局药品审评中心CDE受理品种目录可以看出，国内泡沫剂国内泡沫剂研发竞赛已经悄然拉开了序幕。最近两年最为热门的泡沫剂仿制品种当属米诺地尔泡沫剂和盐酸米诺环素泡沫剂。目前CDE已经受理了浙江三生蔓迪药业有限公司（已获批）、辰光（天津）制药有限公司、山西振东安欣生物制药有限公司、山东致泰医药技术有限公司/济宁为民制药有限公司、广东红珊瑚药业有限公司等5家公司的米诺地尔泡沫剂仿制药上市申请。而山西振东安欣的盐酸米诺环素泡沫剂仿制药上市申请也于今年6月份获得CDE受理。可以看出，目前国内药企于泡沫剂这一剂型的重视程度和研发热情较前些年有了明显的高涨。这其中的热情并不难理解。米诺地尔作为一种有效的脱发治疗药物，其泡沫剂型相比传统搽剂具有更好的使用体验和患者依从性。随着脱发问题的日益普遍和年轻化，米诺地尔泡沫剂的市场需求持续增长。而盐酸米诺环素泡沫剂在治疗痤疮方面显示出良好的疗效和安全性，且痤疮是一种常见的皮肤问题，尤其在青少年和年轻成人中发病率较高，因此该药物的市场需求也很大。此外，泡沫剂作为一种高端药物递送系统，处方工艺复杂，仿制难度大，进入壁垒高，一旦成功研发并上市，将能够在一定程度上避免激烈的市场竞争。且由于泡沫剂研发难度大、成本高，市场上同类竞品相对较少，这有助于产品在市场上占据一定的份额，并享受较高的利润空间。与传统仿制药相比，泡沫剂这种高端制剂由于技术壁垒和独特优势，受集采政策的影响相对较小，这就意味着在集采压力下，其仍能保持一定的价格优势和市场竞争力。三、结语随着米诺地尔泡沫剂、盐酸米诺环素泡沫剂的相继获批上市，国内泡沫剂市场正式迎来了一个全新的竞争格局。这两款产品的上市到来不仅为患者提供了更多的治疗选择，也将极大地激发国内药企对泡沫剂研发的热情和动力。可以预见，在未来将会有更多的泡沫剂产品涌现市场，为患者带来福音，这也将促使国内药企在泡沫剂研发创新、质量控制、市场推广等方面不断提升自身实力，推动企业自身发展和中国医药产业进步。药事纵横征稿启事

优先审批上市批准临床3期引进/卖出医药出海

2024-11-15

·PRNewswire

Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada

MALVERN, Pa., Nov. 15, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream (calcipotriene and betamethasone dipropionate) in Canada through Endo's subsidiary Paladin Pharma Inc. "We look forward to working with MC2 to make Wynzora® Cream available to Canadians who suffer from plaque psoriasis," said Livio Di Francesco, Vice President and General Manager of Paladin. "If approved by Health Canada, Wynzora® Cream's unique formulation and clinical profile will offer patients a new treatment option designed for convenience of use in daily routines." "Paladin has an experienced and dedicated team, and we're pleased to work with them to introduce Wynzora® Cream in Canada," said Jesper J. Lange, Chief Executive Officer, MC2 Therapeutics. "The agreement aligns with our strategy to make Wynzora® Cream available to as many patients suffering from plaque psoriasis as possible globally." Wynzora® Cream was approved in the US by the FDA on July 20, 2020 and launched in Europe on February 18, 2022. About Wynzora® Cream Wynzora® Cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis, including scalp psoriasis, in adults. Its dual mode of action is targeting the hallmark cytokines IL-23 and IL-17A/F immune axis and TNF-α expression in a single product. Wynzora® Cream is uniquely enabled by MC2's formulation and drug delivery system PAD Technology™, allowing a convenient-to-use aqueous formulation. About Endo and Paladin Pharma Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at or connect with us on LinkedIn. Paladin Pharma Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. Paladin has a focused marketing, medical and sales organization that has helped it evolve into one of Canada's leading specialty pharmaceutical companies. Paladin is an operating company of Endo, Inc. For more information, visit . About MC2 Therapeutics () MC2 Therapeutics is a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation. Its pioneering approach in immunology is anchored in a deep understanding of skin biology, clinical expertise and cross-silo thinking. Besides Wynzora® Cream, MC2 has a pipeline that includes two first-in-class drug candidates, both in Phase 2 clinical development. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements including, but not limited to, the statements by Messrs. Di Francesco and Lange and any statements relating to product development and commercialization, treatment options and therapies, regulatory approval, efficacy and product availability. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, unfavorable or delayed regulatory review, uncertainties in and the timing for regulatory approval, changes in competitive, market or regulatory conditions, and consumer and physician acceptance of current and new products. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in Endo's press releases and in its public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Endo's most recent Form 10-Q and in Endo's final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with Endo's Form S-1/A. SOURCE Endo, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准引进/卖出临床2期

100 项与倍他米松二丙酸酯/卡泊三醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	D05AX52	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
头皮银屑病	英国	Almirall SA	2021-07-29
银屑病	瑞士	LEO Pharma A/S	2008-09-04
斑块状银屑病	美国	LEO Pharma A/S	2008-05-09
寻常性银屑病	美国	LEO Pharma A/S	2006-01-09

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
头皮皮肤病	临床3期	中国	Leo Pharma, Inc.	2010-09-01
银屑病关节炎	临床2期	法国	Leo Pharma, Inc.	2009-01-01
过敏性皮肤反应	临床1期	美国	MC2 Therapeutics Ltd.	2019-02-13
红斑	临床1期	日本	Leo Pharma, Inc.	2015-03-01
晒伤	临床1期	日本	Leo Pharma, Inc.	2015-03-01
光毒性皮炎	临床1期	日本	Leo Pharma, Inc.	2010-12-01
瘙痒	临床1期	日本	Leo Pharma, Inc.	2010-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04227288 (CTgov)	临床4期	甲银屑病	6	Enstilar Foam	窪壓壓獵構鹽蓋製艱壓(鹽餘製壓築餘憲衊選淵) = 願簾襯夢網願膚顧夢獵衊鹹網膚積餘觸壓願窪 (鏇積構壓觸艱範憲廠選, 選膚衊窪餘鹽蓋衊繭網 ~ 鑰構顧構襯觸餘醖壓觸) 更多	-	2025-01-17
NCT05919082 (NEWS) 人工标引	临床3期	斑块状银屑病	604	LEO 90100	膚齋繭觸鏇獵鹽醖糧鏇(鑰鹹憲憲構襯襯簾鹹簾) = Enstilar®在主要终点上相较于得肤宝®（卡泊三醇倍他米松软膏）表现出优效性憲糧遞構繭顧築壓淵醖 (壓獵觸構願膚積襯簾艱 ) 达到更多	积极	2024-05-08
				得肤宝
NCT03308799 (Biospace) 人工标引	临床3期	皮肤色素沉着	-	Calcipotriene+Betamethasone Dipropionate/Calcipotriene (Patients with skin of color (Fitzpatrick IV-VI))	壓繭繭範淵網襯築蓋窪(觸選糧網築範餘蓋範鬱) = 餘淵選鏇顧遞網構鏇遞鑰觸膚選夢衊遞鹹夢製 (築齋夢窪繭膚觸鏇夢糧 ) 更多	积极	2022-09-15
Pubmed 人工标引	N/A	寻常性银屑病	166	Calcipotriene+LEO90100	鑰繭鏇鬱鏇觸醖壓製遞(鹹壓襯鏇願衊觸餘顧鹽) = 艱衊鏇範遞遞蓋遞築醖廠窪築夢範願醖夢襯廠 (鑰願壓鹽網積夢鏇製選, 3.0) 更多	积极	2022-07-18
NCT02668692 (CTgov)	临床3期	寻常性银屑病	213	LEO 80185 gel	窪壓製糧鬱鹽餘憲鑰鹽(艱願築糧糧積鬱艱蓋簾) = 襯鬱醖鑰襯齋獵淵願築範繭壓鹹鑰廠積範簾醖 (觸獵簾顧觸膚觸構餘鏇, 蓋醖遞壓鏇選鏇憲願襯 ~ 構窪製簾襯壓積膚築夢) 更多	-	2021-07-27
NCT02899962 (PSO-LONG trial, Pubmed \| J Am Acad Dermatol) 人工标引	临床3期	斑块状银屑病	545	Cal/BD foam	襯觸選觸壓蓋積衊襯廠(鬱壓壓願窪選築遞淵願) = 選繭鹽構鏇選繭製鏇觸齋顧繭網艱製積觸簾窪 (願艱鏇鹽構顧齋鹹衊衊 ) 更多	优效	2021-05-01
				vehicle foam	襯觸選觸壓蓋積衊襯廠(鬱壓壓願窪選築遞淵願) = 廠夢築廠齋襯夢膚觸鹽齋顧繭網艱製積觸簾窪 (願艱鏇鹽構顧齋鹹衊衊 ) 更多
NCT03819218 (CTgov)	临床2期	寻常性银屑病	7	MC2-01 cream	醖廠壓繭鹽醖夢衊築構(鹽艱壓選壓鹹簾鹹鬱願) = 鹽衊衊鬱簾願壓鑰網獵鹹獵築壓願膚窪積獵衊 (構顧構鹹艱遞選蓋衊窪, 願鏇衊壓糧築餘範觸醖 ~ 蓋窪製簾鹽齋壓構築構) 更多	-	2021-02-21
NCT03506477 (CTgov)	临床4期	斑块状银屑病	25	Enstilar® foam (Enstilar® Foam)	膚糧衊遞鹹製選夢鹽鏇(醖襯製網鏇鏇積壓鑰糧) = 鬱壓夢憲廠鹹獵艱繭廠鑰醖遞繭網製鏇淵糧襯 (遞簾蓋醖觸繭製膚鏇遞, 糧壓膚齋艱糧廠淵淵積 ~ 廠簾選醖範壓鬱積積衊) 更多	-	2021-01-20
				Vehicle Foam (Vehicle Foam)	膚糧衊遞鹹製選夢鹽鏇(醖襯製網鏇鏇積壓鑰糧) = 鬱製構蓋餘鬱選夢構憲鑰醖遞繭網製鏇淵糧襯 (遞簾蓋醖觸繭製膚鏇遞, 願鏇衊壓壓膚糧遞鬱淵 ~ 鏇衊憲繭襯鏇醖鹹壓鹽) 更多
NCT03806790 (CTgov)	临床3期	寻常性银屑病	182	LEO 90100 foam (LEO 90100 Foam)	構衊積夢窪鬱製壓選窪(壓壓鹽衊積鹽遞餘鏇餘) = 鹽觸蓋鏇醖鹽製觸築觸醖糧窪選襯夢顧繭膚艱 (繭簾淵獵簾餘顧窪製遞, 築蓋糧膚積蓋積網鑰艱 ~ 蓋衊廠繭觸鬱襯簾繭蓋) 更多	-	2020-12-16
				Dovobet® ointment (Dovobet® Ointment)	構衊積夢窪鬱製壓選窪(壓壓鹽衊積鹽遞餘鏇餘) = 簾簾獵觸廠齋積鬱膚繭醖糧窪選襯夢顧繭膚艱 (繭簾淵獵簾餘顧窪製遞, 願簾糧餘築艱壓艱鏇製 ~ 簾鏇廠顧壓簾範糧鹽蓋) 更多
NCT03802344 (CTgov)	临床3期	寻常性银屑病	498	MC2-01 cream (MC2-01 Cream)	願簾遞網齋憲襯糧築觸(構膚繭壓觸齋壓廠餘餘) = 顧衊構齋糧壓觸觸網醖簾窪鑰顧夢範遞繭艱選 (憲艱獵憲壓醖餘夢鹽範, 醖蓋衊艱夢壓鹽獵膚獵 ~ 構醖餘淵獵憲糧壓醖窪) 更多	-	2020-11-27
				Cal/BDP combination (Cal/BDP Combination)	願簾遞網齋憲襯糧築觸(構膚繭壓觸齋壓廠餘餘) = 鏇窪選製膚鏇鹹願顧網簾窪鑰顧夢範遞繭艱選 (憲艱獵憲壓醖餘夢鹽範, 鹹淵製獵範鬱糧蓋膚繭 ~ 鏇範襯鏇鹹憲廠鑰鬱艱) 更多